Chapter 86. Allogeneic Hematopoietic Cell Transplantation for Solid Tumors

  1. Karl G. Blume MD1,
  2. Stephen J. Forman MD2 and
  3. Frederick R. Appelbaum MD3
  1. Richard W. Childs and
  2. Ramaprasad Srinivasan

Published Online: 26 OCT 2007

DOI: 10.1002/9780470987070.ch86

Thomas' Hematopoietic Cell Transplantation, Third Edition

Thomas' Hematopoietic Cell Transplantation, Third Edition

How to Cite

Childs, R. W. and Srinivasan, R. (2003) Allogeneic Hematopoietic Cell Transplantation for Solid Tumors, in Thomas' Hematopoietic Cell Transplantation, Third Edition (eds K. G. Blume, S. J. Forman and F. R. Appelbaum), Blackwell Publishing Ltd, Oxford, UK. doi: 10.1002/9780470987070.ch86

Editor Information

  1. 1

    Professor of Medicine, Division of Bone Marrow Transplantation, Department of Medicine, Stanford University, Stanford, California

  2. 2

    Director, Department of Hematology and Bone Marrow Transplantation; Staff Physician, Division of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California

  3. 3

    Member and Director, Clinical Research Division, Fred Hutchinson Cancer Research Center; Professor and Head, Division of Medical Oncology, University of Washington School of Medicine, Seattle, Washington

Publication History

  1. Published Online: 26 OCT 2007
  2. Published Print: 4 DEC 2003

ISBN Information

Print ISBN: 9781405112567

Online ISBN: 9780470987070

SEARCH

Keywords:

  • tumors;
  • hematopoietic cell transplantation (HCT);
  • myeloablative conditioning;
  • immunotherapy;
  • graft-vs-tumor (GVT) effect

Summary

This chapter contains sections titled:

  • Allogeneic transplantation as immunotherapy: the graft-vs.-leukemia effect

  • The immune system and solid tumors

  • Solid tumors as a GVT target

  • Use of nonmyeloablative conditioning in allogeneic transplantation for solid tumors

  • Clinical results of NMHCT in solid tumors

  • Emerging role of NMHCT for RCC

  • Toxicities and limitations of NMHCT in metastatic RCC

  • NMHCT in melanoma

  • NMHCT in other solid tumors

  • Mechanisms underlying GVT effects in solid tumors

  • Future directions